Takeda Pharmaceutical Company Limited

Atsuko Ochida

Satoshi Yamamoto

Junya Shirai

Yoshiyuki Fukase

Yoshihide Tomata

Tsuneo Oda

Naoki Ishii

Hidekazu Tokuhara

Shoji Fukumoto

Mitsunori Kono

Tomoya Yukawa

Takashi Imada

Ayumu Sato

Michiko Tawada

Yusuke Sasaki

Kazuko Yonemori

Shinji Nakamura

Tsuneo Yasuma

Xin Liu

Masami Yamada

Hiroyuki Watanabe

Kazuaki Takami

Nobuyuki Takakura

Tomoaki Hasui

Satoshi Mikami

Shuji Kitamura

Shinji Morimoto

Yoshihiro Banno

Tohru Yamashita

Yoshito Terao

Hideyuki Nakagawa

Minoru Ikoma

Sachie Morimoto

Shotaro Miura

Mitsunori Kouno

Kei Masuda

Ryokichi Koyama

Norio Oyabu

The present invention relates to compound (I) or a salt thereof which has a RORγt inhibitory action. In the formula (I), each symbol is as defined in the specification.

Heterocyclic amide compounds having an RORvt inhibitory action

The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. In the formula (I), each symbol is as defined in the specification. 

Heterocyclic amide compounds having RORyT inhibitory action

Amide compound

Provided are heterocyclic compounds having a ROR&#x3b3;t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. wherein each symbol is as defined in the specification.

Heterocyclic compound

The problem of the present invention is to provide a compound having a superior ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The present invention provides a heterocyclic compound having an ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): whereinAr is a the partial structure (1) to the partial structure (5),Q is a bivalent group selected from the group consisting of (Ia)-(If), andB is a ring optionally having substituent(s),or a salt thereof.

The present invention provides a heterocyclic compound having a ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.or a salt thereof.

The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Aromatic ring compound

A heterocyclic compound having an ROR&#x3b3;t inhibitory activity, which is a compound of formula (I) or a salt thereof is provided. The compound has ring A, which is an optionally substituted cyclic group and is bound to a pyrazole ring though Q. Q is a bond, optionally substituted Calkylene, optionally substituted Calkenylene, or optionally substituted Calkynylene. Ris a substituent. Ring B is a thiazole ring, an isothiazole ring or a dihydrothiazole ring, each of which is optionally further substituted by a substituent in addition to R. Ris an optionally substituted cyclyl-carbonyl-Calkyl group, an optionally substituted aminocarbonyl-Calkyl group, an optionally substituted cyclyl-Calkyl group, an optionally substituted cyclyl-Calkylamino-carbonyl group, an optionally substituted aminocarbonyl-Calkenyl group, an optionally substituted Calkylcarbonylamino-Calkyl group, an optionally substituted cyclyl-aminocarbonyl group, an optionally substituted cyclyl-carbonyl group or an optionally substituted non-aromatic heterocyclic group.

The present invention provides a fused heterocyclic compound having an ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I'): wherein each symbol is as defined in the specification, provided that 2-(2-((4-cyanophenyl)amino)-2-oxoethoxy)-N-(9-ethyl-9H-carbazol-3-yl)acetamide and N-(4-cyanophenyl)-N&#x2032;-(9-ethyl-9H-carbazol-3-yl)-3-methylpentanediamide are excluded, or a thereof.

Condensed heterocyclic compound

Growing community of inventors

Kanagawa, Japan

Atsuko Ochida